Major depressive disorder: mechanism-based prescribing for personalized medicine
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Individual patients with depression present with unique symptom clusters - before, during, and even after treatment. The prevalence of persistent, unresolved symptoms and their contribution to patient functioning and disease progression emphasize the importance of finding the right treatment choice at the onset and the utility of switching medications based on suboptimal responses. Our primary goal as clinicians is to improve patient function and quality of life. In fact, feelings of well-being and the return to premorbid levels of functioning are frequently rated by patients as being more important than symptom relief. However, functional improvements often lag behind resolution of mood, attributed in large part to persistent and functionally impairing symptoms - namely, fatigue, sleep/wake disturbance, and cognitive dysfunction. Thus, patient outcomes can be optimized by deconstructing each patient's depressive profile to its component symptoms and specifically targeting those domains that differentially limit patient function. This article will provide an evidence-based framework within which clinicians may tailor pharmacotherapy to patient symptomatology for improved treatment outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
MacDonald, A. W., Cohen, J. D., Stenger, V. A., & Carter, C. S. (2000) · Science · doi:10.1126/science.288.5472.1835 · Cited by 3,666
Drevets, W. C., Price, J. L., & Furey, M. L. (2008) · Brain Structure and Function · doi:10.1007/s00429-008-0189-x · Cited by 2,241 · cited 1×
“62,71,76 Abbreviations: 5HT, 5-hydroxytryptamine or serotonin; DAT, dopamine transporter; NDRi, norepinephrine–dopamine reuptake inhibitor; NeT, norepinephrine transporter; SeRT, serotonin transporter; SNRi, serotonin–norepinephrine reuptake inhibitor; SSRi, selective serotonin reuptake inhibitor;…”
Cipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., Watanabe, N., Nakagawa, A., Omori, I. M., McGuire, H., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60046-5 · Cited by 1,654
The Economic Burden of Depression in the United States: How Did It Change Between 1990 and 2000?
Greenberg, P. E., Kessler, R. C., Birnbaum, H. G., Leong, S. A., Lowe, S. W., Berglund, P. A., & Corey-Lisle, P. K. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n1211 · Cited by 1,280
The role of dopamine in the pathophysiology of depression
Dunlop, B. W., & Nemeroff, C. B. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.3.327 · Cited by 1,244 · cited 1×
“Aberrant DA and NE signaling is thought to adversely influence motivation, an essential driver of goal-directed behaviors and related executive functions.(65,66) Impaired 5HT neurotransmission forms, at least in part, the pathophysiologic basis for anhedonia, guilt, and similar ‘negative affects’ of depression.”
Koolschijn, P. C. M. P., van Haren, N. E. M., Lensvelt‐Mulders, G. J. L. M., Hulshoff Pol, H. E., & Kahn, R. S. (2009) · Human Brain Mapping · doi:10.1002/hbm.20801 · Cited by 902
Kessler, R. C. (2012) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2011.11.005 · Cited by 871
Penninx, B. W., Milaneschi, Y., Lamers, F., & Vogelzangs, N. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-129 · Cited by 839
McKinnon, M. C., Yucel, K., Nazarov, A., & MacQueen, G. M. (2009) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0905 · Cited by 742
Kennedy, S. H., Evans, K. R., Krüger, S., Mayberg, H. S., Meyer, J. H., McCann, S., Arifuzzman, A. I., Houle, S., & Vaccarino, F. J. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.6.899 · Cited by 710 · cited 2×
“sants can reverse functional changes observed in depressed patients.(58) These and related advances in translational”
Report by the ACNP Task Force on Response and Remission in Major Depressive Disorder
Rush, A. J., Kraemer, H. C., Sackeim, H. A., Fava, M., Trivedi, M. H., Frank, E., Ninan, P. T., Thase, M. E., Gelenberg, A. J., Kupfer, D. J., et al. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301131 · Cited by 707
Neurotransmitter Receptor and Transporter Binding Profile of Antidepressants and Their Metabolites
Owens, M. J., Morgan, W. N., Plott, S. J., & Nemeroff, C. B. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37161-7 · Cited by 676
Bang-Andersen, B., Ruhland, T., Jørgensen, M., Smith, G., Frederiksen, K., Jensen, K. G., Zhong, H., Nielsen, S. M., Hogg, S., Mørk, A., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101459g · Cited by 606 · cited 1×
“Specifically, serotonin 5HT 2A and 5HT 7 receptors have been linked to sleep, circadian rhythm, and mood.(94,121) The 5HT 2A”
Judd, L. L., Akiskal, H. S., Maser, J. D., Zeller, P. J., Endicott, J., Coryell, W., Paulus, M. P., Kunovac, J. L., Leon, A. C., Mueller, T. I., et al. (1998) · Journal of Affective Disorders · doi:10.1016/s0165-0327(98)00138-4 · Cited by 590
Cognitive control and brain resources in major depression: An fMRI study using the n-back task
Harvey, P.-O., Fossati, P., Pochon, J.-B., Levy, R., LeBastard, G., Lehéricy, S., Allilaire, J.-F., & Dubois, B. (2005) · NeuroImage · doi:10.1016/j.neuroimage.2005.02.048 · Cited by 534
Moylan, S., Maes, M., Wray, N. R., & Berk, M. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.33 · Cited by 529
How might circadian rhythms control mood? Let me count the ways
McClung, C. A. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.02.019 · Cited by 507
Cognitive functioning in major depression – a summary
Hammar, Å. (2009) · Frontiers in Human Neuroscience · doi:10.3389/neuro.09.026.2009 · Cited by 491 · cited 1×
“Sustained cognitive impairments following an MDE frequently lead to frustration, low self-esteem, and impaired interpersonal relationships in the family, workplace, and social network.(6,105) Further, cognitive dysfunction is associated with the cumulative duration of depressive episodes, emphasizing the need for earl…”
Neurocognitive deficits and disability in major depressive disorder
Jaeger, J., Berns, S., Uzelac, S., & Davis-Conway, S. (2006) · Psychiatry Research · doi:10.1016/j.psychres.2005.11.011 · Cited by 484
Katona, C., Hansen, T., & Olsen, C. K. (2012) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3283542457 · Cited by 445
McIntyre, R. S., Lophaven, S., & Olsen, C. K. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714000546 · Cited by 433
Who are the long sleepers? Towards an understanding of the mortality relationship
Grandner, M. A., & Drummond, S. P. A. (2007) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2007.03.010 · Cited by 432
Lam, R. W., Kennedy, S. H., Grigoriadis, S., McIntyre, R. S., Milev, R., Ramasubbu, R., Parikh, S. V., Patten, S. B., & Ravindran, A. V. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.06.041 · Cited by 431
How Should Remission From Depression Be Defined? The Depressed Patient’s Perspective
Zimmerman, M., McGlinchey, J. B., Posternak, M. A., Friedman, M., Attiullah, N., & Boerescu, D. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.148 · Cited by 431 · cited 1×
“levels of functioning are frequently rated by patients as more important than symptom relief, yet functional improvements often lag behind resolution of mood.(6,30) Reasons for delayed functional recovery are only partly characterized; however, the symptoms that most impair function are the same symptoms Table 1 DSM-5…”
Cognitive impairment in the remitted state of unipolar depressive disorder: A systematic review
Hasselbalch, B. J., Knorr, U., & Kessing, L. V. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.11.011 · Cited by 406 · cited 1×
“In a recent systematic review, nine of eleven studies reported that patients with remitted unipolar depression had decreased performance on neuropsychological tests compared with never depressed controls.(104) Sustained cognitive impairments following an MDE frequently lead to frustration, low self-esteem, and impaire…”
McKnight, P. E., & Kashdan, T. B. (2009) · Clinical Psychology Review · doi:10.1016/j.cpr.2009.01.005 · Cited by 400 · cited 4×
“Sustained cognitive impairments following an MDE frequently lead to frustration, low self-esteem, and impaired interpersonal relationships in the family, workplace, and social network.(6,105) Further, cognitive dysfunction is associated with the cumulative duration of depressive episodes, emphasizing the need for earl…”
InfluentialThe role of cognitive impairment in general functioning in major depression
Baune, B. T., Miller, R., McAfoose, J., Johnson, M., Quirk, F., & Mitchell, D. (2010) · Psychiatry Research · doi:10.1016/j.psychres.2008.12.001 · Cited by 378
The importance of norepinephrine in depression
Briley, M., & Chantal, M. (2011) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s19619 · Cited by 373 · cited 1×
“Aberrant DA and NE signaling is thought to adversely influence motivation, an essential driver of goal-directed behaviors and related executive functions.(65,66) Impaired 5HT neurotransmission forms, at least in part, the pathophysiologic basis for anhedonia, guilt, and similar ‘negative affects’ of depression.”
The many faces of fatigue in major depressive disorder
Demyttenaere, K., De Fruyt, J., & Stahl, S. M. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145704004729 · Cited by 288
5-HT7 receptor inhibition and inactivation induce antidepressantlike behavior and sleep pattern
Hedlund, P. B., Huitron-Resendiz, S., Henriksen, S. J., & Sutcliffe, J. G. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.05.012 · Cited by 281 · cited 1×
“96–100 Additional long-term studies are required to further evaluate the clinical relevance of these pharmacologic properties.”
Mørk, A., Pehrson, A., Brennum, L. T., Nielsen, S. M., Zhong, H., Lassen, A. B., Miller, S., Westrich, L., Boyle, N. J., Sánchez, C., et al. (2012) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.189068 · Cited by 271
McClintock, S. M., Husain, M. M., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Trivedi, M. H., Cook, I., Morris, D., Warden, D., & Rush, A. J. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31820ebd2c · Cited by 234 · cited 2×
“As noted, fatigue, sleep/ wake disturbances, and cognitive dysfunction are among the most troublesome symptoms, as they commonly persist after antidepressant therapy and have a disparate impact on patient functioning.(18,29,31,80) Clinicians may wish to identify and specifically target these and other baseline symptom…”
Fava, M., Graves, L. M., Benazzi, F., Scalia, M. J., Iosifescu, D. V., Alpert, J. E., & Papakostas, G. I. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1113 · Cited by 229
Defining and Measuring Functional Recovery from Depression
Greer, T. L., Kurian, B. T., & Trivedi, M. H. (2010) · CNS Drugs · doi:10.2165/11530230-000000000-00000 · Cited by 222
Epigenetic mechanisms of depression
Nestler, E. J. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.4291 · Cited by 217
Partial remission, residual symptoms, and relapse in depression
Paykel, E. S. (2008) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2008.10.4/espaykel · Cited by 194
Patten, S. B., Kennedy, S. H., Lam, R. W., O'Donovan, C., Filteau, M. J., Parikh, S. V., & Ravindran, A. V. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.06.044 · Cited by 148 · cited 3×
“severity of symptoms at each visit.(11,13,14) However, clinicians may find it more practical to ask about symptoms directly through the course of the patient interview.”
Montgomery, S. A., Nielsen, R. Z., Poulsen, L. H., & Häggström, L. (2014) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2424 · Cited by 143 · cited 1×
“9 47”
Renoir, T. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00045 · Cited by 107 · cited 1×
“77 The clinical manifestation of these pharmacologic differences was recently illustrated in a meta-analysis of 117 randomized controlled trials (25,928 participants) comparing clinical response and discontinuation rates of antidepressants.”
Strategies to enhance the therapeutic efficacy of antidepressants: targeting residual symptoms
Kurian, B. T., Greer, T. L., & Trivedi, M. H. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.53 · Cited by 73
Hasselbalch, B. J., Knorr, U., Hasselbalch, S. G., Gade, A., & Kessing, L. V. (2013) · European Psychiatry · doi:10.1016/j.eurpsy.2012.03.004 · Cited by 70 · cited 1×
“Further, cognitive dysfunction is associated with the cumulative duration of depressive episodes, emphasizing the need for early detection and targeted treatment.(106) While additional studies are required to elucidate the neurochemical basis of persistent cognitive deficits, recent imaging studies suggest that hypoac…”
Greer, T. L., Sunderajan, P., Grannemann, B. D., Kurian, B. T., & Trivedi, M. H. (2014) · Depression Research and Treatment · doi:10.1155/2014/627863 · Cited by 63
A practical approach to prescribing antidepressants
Shultz, E., & Malone, D. A. (2013) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.80a.12133 · Cited by 27
Cited by
Luedtke, A., Sadikova, E., & Kessler, R. C. (2019) · Clinical Psychological Science · doi:10.1177/2167702618815466 · Cited by 143
Iosifescu, D. V., Jones, A., O’Gorman, C., Streicher, C., Feliz, S., Fava, M., & Tabuteau, H. (2022) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.21m14345 · Cited by 135
Gauthier, G., Guérin, A., Zhdanava, M., Jacobson, W., Nomikos, G., Merikle, E., François, C., & Perez, V. (2017) · BMC Psychiatry · doi:10.1186/s12888-017-1385-0 · Cited by 70
“Antidepressant drugs constitute the standard of care for MDD [6, 7, 14], whereby most patients will receive a selective serotonin reuptake inhibitor (SSRI) as first-line pharmacotherapy [15].”
BackgroundPatient-reported outcome measures for life engagement in mental health: a systematic review
McIntyre, R. S., Ismail, Z., Watling, C. P., Weiss, C., Meehan, S. R., Musingarimi, P., & Thase, M. E. (2022) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-022-00468-5 · Cited by 48
Haghighi, M., Ludyga, S., Rahimi, B., Jahangard, L., Ahmadpanah, M., Torabian, S., Esnaashari, F., Nazaribadie, M., Bajoghli, H., Sadeghi Bahmani, D., et al. (2017) · Psychiatry Research · doi:10.1016/j.psychres.2017.02.012 · Cited by 24
Metadata
- Authors
- Lapolla, T., Saltiel, P., & Silvershein, D.
- Venue
- Neuropsychiatric Disease and Treatment
- Publisher
- Informa UK Limited
- Published
- 2015-03
- Volume
- 11
- Pages
- 875
- ISSN
- 1176-6328 (ISSN-L)
- 1178-2021
- OpenAlex
- W2069934545
- Cited by
- 86
- References
- 44
- FWCI
- 6.13
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.